Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14735277 | 0.83 | ALDH2 (0.42) | MAPTKDM4ETHRBALDH2GPR119 | |
| SCHEMBL14735051 | 0.79 | GPR119 (0.44) | MAPTKDM4ETHRBDPP4GPR119 | |
| SCHEMBL14887070 | 0.73 | STS (0.40) | MAPTKDM4ETHRBGPR119ALDH1A1 | |
| SCHEMBL25941307 | 0.71 | DPP4 (0.46) | MAPTKDM4ETHRBALDH2DPP4 | |
| SCHEMBL30493204 | 0.71 | DPP4 (0.46) | MAPTKDM4ETHRBALDH2DPP4 | |
| SCHEMBL14735000 | 0.70 | GPR119 (0.41) | KDM4EGPR119ALDH1A1 | |
| SCHEMBL14735601 | 0.70 | GPR119 (0.42) | KDM4EGPR119ALDH1A1 | |
| SCHEMBL14735273 | 0.68 | PDE4B (0.50) | GPR119ALDH1A1 | |
| SCHEMBL18864007 | 0.68 | GPR119 (0.46) | KDM4EDPP4GPR119 | |
| SCHEMBL14735473 | 0.68 | MEN1 (0.47) | MAPTKDM4ETHRBGPR119ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2565192-B9 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| EP-2565192-B1 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-08-12 | — | — | EP | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2565192-A1 | ANTICANCER AGENT | The University of Tokyo (JP) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102776-A1 | ANTICANCER AGENT | PIM1, PIM3, PIM2 | MAPT 4754/4885KDM4E 540/4885THRB 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.